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Ahmanson Foundew therapeutic targets, agents, and strategies are needed to prevent and treat heart failure (HF) after a decade
of failed research efforts to improve long-term patient outcomes, especially in patients after hospitalization for HF.
Conceptually, an accurate assessment of left ventricular structure is an essential step in the development of novel
therapies because heterogeneous pathophysiologies underlie chronic HF and hospitalization for HF. Improved left
ventricular characterization permits the identiﬁcation and targeting of the intrinsic fundamental disease-modifying
pathways that culminate in HF. Interstitial heart disease is one such pathway, characterized by extracellular matrix
(ECM) expansion that is associated with mechanical, electrical, and vasomotor dysfunction and adverse outcomes.
Previous landmark trials that appear to treat interstitial heart disease were effective in improving outcomes.
Advances in cardiovascular magnetic resonance now enable clinicians and researchers to assess the interstitium
and quantify ECM expansion using extracellular volume fraction measures and other derangements in
cardiovascular structure. These capabilities may provide a mechanistic platform to advance understanding of the
role of the ECM, foster the development of novel therapeutics, and target speciﬁc disease-modifying pathways
intrinsic to the ventricle. Refocusing on the interstitium may potentially improve care through the identiﬁcation and
targeted treatment of key patient subgroups. (J Am Coll Cardiol 2014;63:2188–98) ª 2014 by the American
College of Cardiology FoundationThe Need to Refocus on the
Myocardial Interstitium in Heart Failure
Unsuccessful efforts to lower high event rates in heart
failure patients. Heart failure (HF) is the most common
reason for hospitalization in older patients. Mortality and
rehospitalization rates 90 days after hospitalization for
heart failure (HHF) remain as high as 15% and 30%,
respectively (1). Accordingly, HHF incurs the greatest costs
among Medicare patients (2). These high event rates after
HHF require urgent attention (2,3). Yet, over the past
decade, a strikingly high number of phase 3 trials attempting
to improve intermediate- to long-term clinical outcomes
failed to produce positive results. One probable reason why
beneﬁts observed during phase 2 trials have not translated
into beneﬁts in large phase 3 trials is a lack of in-depth basic& Vascular Institute Department of Medicine, University of
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structure and function (4,5).
In parallel with unsuccessful clinical trials, efforts to
develop and adhere to performance measures to improve
HF outcomes have not been effective (6). Reﬂecting our
incomplete understanding (7) and the paucity of evidence,
current HF performance measures place no emphasis on
identifying and addressing the fundamental mechanisms
of HF (8). The cascade of derangements that culminate
in HF and HHF are complex and heterogeneous, with
diverse underlying cardiac substrates and diverse initiating
and amplifying mechanisms that are incompletely under-
stood (7). If therapeutic advances are to be made, it is
critical to identify both the modiﬁable and nonmodiﬁable
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Abbreviations
and Acronyms
CMR = cardiovascular
magnetic resonance
ECM = extracellular matrix
ECV = extracellular
volume fraction
Gd = gadolinium
HF = heart failure
HHF = hospitalization for
heart failure
LGE = late gadolinium
enhancement
LV = left ventricular
RAAS = renin-angiotensin-
aldosterone system
TNF = tumor necrosis factor
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2189diastolic function and contribute to post-discharge mor-
bidity and mortality (9).
Extracellular matrix as a therapeutic target. Considerable
data suggest that both preventing and ameliorating extracellular
matrix (ECM) expansion from excess collagen remain impor-
tant components of therapeutic success (10). ECMexpansion is
one of the hallmarks of pathological LV remodeling (11–16)
and may promote disease progression in many causes of HF
(11–14). This concept is not new (11,17), but the importance
of ECM expansion in the hierarchy of changes in HF and its
value as a therapeutic target remain unclear.
Importantly, ECM expansion from excess collagen and
its adverse effects are modiﬁable. Collagen regression occurs
in humans after treatment with angiotensin-converting en-
zyme inhibitors (18,19), angiotensin receptor blockers (20),
and mineralocorticoid antagonists (21). Cardiac functional
parameters and coronary ﬂow reserve then improve (18–21).
Regression of the collagen volume fraction appears modest
in these studies, limited to w20% relative change and 1%
absolute change over w10 months. Nonetheless, these
agents improved outcomes in landmark large-scale trials
with longer treatment duration.
Renin-angiotensin-aldosterone system (RAAS) activation
occurs in the myocardium (22), and RAAS modulators im-
prove survival regardless of blood pressure–lowering effects
(23,24), even in the absence of clinical HF (24). These
agents also decrease the risk of HHF (25–30). Patients with
HF appear to beneﬁt most from RAAS modulation if there
is underlying myocardial ﬁbrosis (21,31). Serelaxin, the most
recent drug generating promising results in HHF patients
(32), is known to reverse myocardial ECM expansion and
myocardial ﬁbrosis (33,34).Table 1
Interstitial Heart Disease Can Occur as a
Final Common Pathway From a Variety of
Myocardial Insults*
Condition Example
Genetic disorders Hypertrophic cardiomyopathy (125,126)
Toxin exposures Smoke (127–129), adriamycin (doxorubicin) (130)
Infections Chagas disease (131), viral myocarditis (132,133)
Inﬂammation Sarcoidosis (134,135), autoimmune myocarditis (136),
human leukocyte antigen mismatches in cardiac
transplants (137)
Chronic metabolic
diseases
Diabetes (43), chronic kidney disease (138),
hypertension (62)
Structural heart
disease
Aortic stenosis (139), chronic coronary insufﬁciency (80),
nonischemic dilated cardiomyopathy (61)
*ECM expansion may or may not occur with myocyte loss (Fig. 1).Vulnerability Associated With
Interstitial Heart Disease
Interstitial heart disease. More than 20 years ago in the
Journal, Karl Weber (17) crystallized the concept of “inter-
stitial heart disease,” characterized by myocardial ECM
expansion from excess collagen based on pioneering work by
his group and others. Within this paradigm, the myocar-
dium has both myocyte and interstitial compartments that
are regulated independently (11). The activated ﬁbroblast
and the expanded ECM that it regulates assume a central
role in the pathophysiology of HF and pathological LV
hypertrophy (11). Maladaptive ECM changes perturb
myocardial architecture and functional properties, occurring
speciﬁcally as a result of ﬁbroblast activity rather than
myocyte activity (11,17).
Consequences of increased myocardial collagen content
include mechanical (18,20,21), electrical (35–38), and vaso-
motor (19) dysfunction and diminished tolerance to ischemic
insults (39–41)dall elements of cardiac vulnerability (42).
Vulnerable interstitium has been reported in sudden cardiac
death victims (38), and bandlike myocardial ﬁbrosis canresemble hepatic ﬁbrosis patterns
seen in cirrhosis (43). Similar to
other organs (44), ﬁbrosis in the
heart also disrupts organ archi-
tecture and culminates in organ
dysfunction, with an important
difference being that the heart is a
highly dynamic organ where the
dysfunction may be more sinister,
leading to greater vulnerability
to adverse outcomes. Fibrosis is
associated with a number of con-
ditions (Table 1) as well as with
normal aging, in which comor-
bidities and heart failure are more
prevalent (45–47).
Interstitial heart disease can
affect myocyte function. ECM
expansion regardless of cause can
have direct deleterious effects on myocyte and cardiac
function. First, speciﬁc activation of myocardial ﬁbro-
blasts (sparing myocytes) causes excess collagen accumu-
lation and myocardial ﬁbrosis and leads to a HF phenotype
in rodents (48). This ﬁnding suggests that there is po-
tential for a primary role of the ﬁbroblast in the develop-
ment of HF.
Second, in cardiac amyloidosis, there is marked myo-
cardial ECM expansion from noncollagenous inter-
stitial amyloid protein accumulation (49–51). Smoldering
myocyte loss occurs, leading to a chronic low-level troponin
increase (52–56). This marked ECM expansion from am-
yloid protein also leads to severe cardiac dysfunction, man-
ifested by a pronounced increase in B-type natriuretic
peptide and an inexorable deterioration in clinical status with
early mortality despite a relatively preserved ejection fraction
(52). This clinical observation is important because, unlike
collagen accumulation, ECM expansion due to accumula-
tion of inert amyloid protein is a primary interstitial process
and not a secondary phenomenon following myocyte injury.
Therefore, ECM expansion, regardless of cause, can have
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function and lead to progressive HF.
Uncertainty about the role of the ﬁbroblast versus
myocyte in interstitial heart disease. The extent to which
primary ECM expansion from ﬁbroblast activation drives
myocyte dysfunction or the extent to which primary myocyte
disease and loss leads to ECM expansion in HF remains
incompletely understood (Fig. 1). There is uncertainty about
where the interstitium ranks in the hierarchy of changes
associated with the development of HF. Nonetheless,
one could postulate that antagonizing ﬁbroblast activation
and myocardial ECM expansion with agents that modu-
late the RAAS (and the adrenergic system that also can
affect ﬁbroblast activity [57]) may contribute to the success
of pharmacological therapy with these drugs in large HF
trials (25–30).
The historical difﬁculty of measuring human ECM
expansion noninvasively has obscured its role in cardiovas-
cular disease for clinicians and researchers (58,59). Whether
ECM expansion is generally a cause or effect of myocar-
dial insults, or both, is still unclear. The phenomenon of
replacement ﬁbrosis after myocyte necrosis (11) creates a
“chicken-and-the-egg” situation: which came ﬁrst when
ECM expansion is encountered, ECM expansion or myo-
cyte loss, if any? Until recently, there has not been a robust
noninvasive method to detect and quantify the full range
of ECM expansion (14,58), rendering it difﬁcult to track
and thus masking its importance. The positive correlationFigure 1 Extracellular Matrix Expansion From Myocardial Fibrosis Ca
The relative contributions of these pathways with or without pre-existing myocyte hypertro
diagram showing how ﬁbroblast activation occurs early in the pathogenesis of heart failure
can contribute to myocyte loss (shown as brown myocytes) with even more ﬁbrosis due to
activation in a myocyte loss pathway occurs late in the pathogenesis of heart failure, after
which occurs early, then is followed by replacement ﬁbrosis from activated ﬁbroblasts. Myo
myocyte loss (brown), ﬁbrillar collagen (blue strands), and ﬁbroblasts (blue spindle-shapbetween LV mass and ECM expansion (43,60–62) suggests
that myocyte loss is not the sole mechanism.Basic Pathogenesis of Interstitial Heart Disease
The ECM functions as a scaffold for cardiomyocytes and
transmits contractile forces. In the absence of cardiac
amyloidosis or myocardial edema, thick type I ﬁbrillar
collagen ﬁbers provide tensile strength and constitute most
of the ECM, even when there is ECM expansion (22). For
this reason, cardiac ECM expansion is often considered
synonymous with myocardial ﬁbrosis. Type III collagen
ﬁbers, which are thinner than type I collagen ﬁbers and
provide elasticity, glycosaminoglycans (e.g., hyaluronan),
glycoproteins, and proteoglycans, are also important ECM
components (11). Fibroblasts are the most numerous cells in
the myocardium and are central to collagen and ECM ho-
meostasis (63). Fibroblasts secrete extracellular procollagen
chains that assemble into ﬁbrils and become cross-linked by
lysyl oxidase. Collagen cross-linking is an important post-
translational modiﬁcation because it increases myocardial
tensile strength (64) and is associated with diastolic dys-
function (18,65) and aging (63). Collagen cross-linking also
resists degradation by matrix metalloproteinases and may
prevent chamber dilation by increasing the integrity of the
cardiac matrix (22).
Myocardial ﬁbrosis and interstitial heart disease occur
when collagen homeostasis becomes dysregulated and excessn Occur Via Different Mechanisms
phy are not known, nor are they mutually exclusive. (Left) A simpliﬁed schematic
(48), leading to reactive interstitial and perivascular ﬁbrosis, which, if severe enough,
replacement ﬁbrosis. (Right) A schematic simpliﬁed diagram showing how ﬁbroblast
myocyte injury (e.g., via necrotic, apoptotic, or autophagic cell death pathways [13]),
cyte hypertrophy without extracellular matrix expansion is not shown. Myocytes (red),
ed cells) are depicted.
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2191collagen accumulates in the interstitium secreted by activated
ﬁbroblasts, termed myoﬁbroblasts. This transformation of
ﬁbroblasts into myoﬁbroblasts involves the expression of
alpha-smooth muscle actin, characteristic of smooth muscle
cells, as well as the appearance of an extensive, synthetically
active endoplasmic reticulum (11). The potential sources of
cardiac myoﬁbroblasts include not only resident cardiac ﬁ-
broblasts (63) but also myoﬁbroblasts from hematopoietic
and endothelial origins (22). Documented sources of myo-
ﬁbroblasts in cardiac ﬁbrosis include circulating and resident
ﬁbroblast progenitors (including ﬁbrocytes), epicardial
epithelial cells undergoing epithelial-to-mesenchymal tran-
sition, and endothelial cells undergoing endothelial-to-
mesenchymal transdifferentiation (22). Cardiac ﬁbroblasts
are sensitive to a wide variety of molecules that affect their
proliferative response to pathological stimuli (63,66).
Drivers of interstitial heart disease. Although many cau-
ses of interstitial heart disease have been identiﬁed (Table 1),
data regarding the precise regulation of collagen and other
components of the ECM and the wide array of molecular
drivers of interstitial heart disease are incomplete (22). Key
mediators include the RAAS system; transforming growth
factor beta, which may affect all cell types involved in cardiac
ﬁbrosis; reactive oxygen species; tumor necrosis factor
(TNF) alpha; and various cytokines that have been reviewed
previously (22,44,63). Importantly, the degrees to which
these factors explain individual variation in ECM expansion
remain unclear. Many elements of the innate and adaptive
immune response participate in the differentiation and
activation of ﬁbroblasts underlying interstitial heart disease,
which were recently reviewed in detail (44). Yet, individuals
appear to vary widely in their tolerance of myocardial insults,
predisposition to ﬁbroblast activation, and subsequent in-
terstitial heart disease. These important issues deserve fur-
ther study because a greater understanding may produce
novel therapies.Noninvasive Metrics of ECM Expansion:
the Extracellular Volume Fraction
A novel measure. It is challenging to understand patho-
physiological processes when they are difﬁcult to measure.
Previously, ECM expansion had been difﬁcult to image and
quantify with any technique (14,58,59,67,68), but techno-
logical advances in cardiovascular magnetic resonance
(CMR) now permit quantiﬁcation of prognostically relevant
ECM expansion (15,16) and its apparent treatment res-
ponse (15). The extracellular volume fraction (ECV) tech-
nique quantiﬁes ECM expansion by measuring the volume
fraction of the interstitial space (Fig. 2). ECM expansion in
the absence of amyloid or edema typically reﬂects excess type
I collagen (12). The change in T1 before and after contrast
allows computation of gadolinium (Gd) contrast concen-
tration. The proportional uptake of Gd contrast in the
myocardium relative to plasma (i.e., 1 – hematocrit) mea-
sures the volume fraction of the myocardial extracellularspace after equilibrium occurs (67,69–71) Isolated post-
contrast myocardial T1 measures are also related to the
collagen volume fraction (72,73), but are confounded by a
variety of clinically relevant factors (74). ECV does not have
similar limitations and exhibits higher correlation with the
collagen volume fraction (75–77). Other non-CMR tech-
niques to estimate ECM expansion have been reviewed
previously and are not discussed here (58,59,68).
ECM expansion measurement introduces a useful inter-
mediate phenotype to demonstrate the efﬁcacy of ECM
regression for novel treatments without resorting to large-
scale trials with prohibitively high costs. Demonstrating
the efﬁcacy of any new therapy is challenging because it
must be incremental to established treatments. Rather than
enrolling thousands of patients to be followed for many
years to demonstrate improved outcomes at an astronomi-
cal cost exceeding available resources, a more realistic initial
approach might be to track the ECM response before
embarking on large-scale ventures.
Quantifying the myocardial ECM has the potential to
assess the risk of death or HHF (15,16) and optimize the
clinician’s choice of diagnostic and therapeutic strategies.
For therapeutic development, ECM expansion measures can
elucidate mechanisms of the response (e.g., ECM regres-
sion), which may then be important for phase 3 trial design
(4). There is considerable heterogeneity in the degree of
ECM expansion in the human myocardium (15,16,49,78)
that may vary in both the timing and extent of a response
to a treatment (21,31). This variability is relevant for trial
design; response to new interventions and risk/beneﬁt ratios
may vary according to the degree of myocardial health
characterized by the degree of myocardial ECM expansion.
Robustness of ECV measures. Myocardial ECV is a
CMRmeasure of ECM expansion and correlates highly with
the collagen volume fraction in human myocardium (R2 ¼
0.7 to 0.9) (75–77,79), regardless of whether it is apparent
in late gadolinium enhancement (LGE) images. ECM
expansion can vary spatially, from focal deposits to diffuse
deposition distributed throughout the entire myocardium
(50,80). Gd tracks thin collagen strands with high ﬁdelity at
the cellular level (81). ECV measurement is reproducible
between CMR scans performed on different days (67,77,82),
translating into fewer subjects required for clinical trials (83).
ECV detects subclinical changes (50,71), but ECV mea-
surement algorithms are not yet standardized and remain
vendor and center dependent (74). ECV also remains limited
by partial volume effects constrained by limited spatial res-
olution whereby larger pixels straddle tissue borders; thus,
ECV is at present not well suited for right ventricular or left
atrial sampling given their thinness (74,84). The same con-
cepts for ECV measurement can be extended to computed
tomography using iodinated contrast (85,86).
ECV is a promising tool for monitoring the ECM
response to therapy. Still, more work regarding optimiza-
tion, automation, and standardization is required (74).
Notably, these limitations also apply to the ejection fraction,
Figure 2
Simpliﬁed Schematic of ECV Measurement From Cardiac Magnetic Resonance Measures Myocardial and Blood T1
Before and After Gd Contrast
ECV measurement exploits the extracellular nature of Gd and measures Gd uptake in the myocardium relative to plasma after equilibrium occurs between the interstitial and
plasma Gd concentrations. The proportional uptake of Gd in the myocardium relative to plasma is then a direct measure of the volume fraction of the myocardial extracellular
space. ECV ¼ extracellular volume fraction; Gd ¼ gadolinium; LV ¼ left ventricular. Reproduced with permission from Wong et al. (16).
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dalities but remains an important clinical metric.
Initial ECV results. Initial results with ECV measures are
encouraging. ECV can detect disease not readily apparent
with conventional LGE (49,50,67,71,75,78,87,88). ECM
expansion measured by CMR in humans correlates posi-
tively with LV mass (15,16,78), reﬂecting previous patho-
logical observations (38,43,60–62). Regarding this issue,
further work is needed to understand complex relationshipsbetween the myocyte and interstitial compartments and how
ECM expansion from myocardial ﬁbrosis or even amyloid
may affect myocyte energetics (13,89). Interestingly, CMR
detects lower ECM in patients receiving RAAS antagonists,
although the magnitude of the reduction appears modest
(15). ECV may be suitable for evaluating serial changes in
ECM (67,82,83).
ECM expansion may rank highly in the hierarchy of
myocardial changes that occur in HF pathophysiology. ECV
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ECM expansion and support the prognostic value of ECM
measures. ECM expansion may be an important modiﬁable
therapeutic target for contemporary and emerging treat-
ments (Table 2).
ECV Versus LGE. LGE is the clinical gold standard for
detecting and measuring myocardial infarction. Although
LGE reﬂects irreversible myocardial damage and provides
important prognostic information (90–96), including the
risk of HHF (97), ECV has advantages over LGE for
quantifying myocardial ﬁbrosis and the interstitial space.
LGE is less suitable for quantifying lesser degrees of
ECM expansion (49,50,71,75,78,87,88) in noninfarcted
myocardium. LGE can erroneously portray nonenhanced
myocardium as normal (16,50,67,71,75,87,98), as shown
in Figure 3. Spatial variation of myocardial ﬁbrosis, which
has a continuous spectrum between focal and diffuse, is
the key feature that renders it potentially detectable on
an LGE image (50). Investigators have not identiﬁed an
optimal LGE threshold to dichotomize the continuum of
myocardial ﬁbrosis into ﬁbrotic or nonﬁbrotic myocar-
dium (99,100).
Cardiac Imaging Versus Biomarkers
Serum biomarkers including galectin-3 and collagen bio-
markers are also associated with mortality, incident HF,
and HHF (101–105) and may prove useful. These bio-
markers are not speciﬁc for the heart and may be inﬂu-
enced by other organ disorders characterized by ﬁbrosis
and by factors that affect their clearance (e.g., renal
function [101]). Galectin-3 is elevated in ﬁbrotic liver
disease (106,107) as well as ﬁbrotic lung disease (108) and
increases in renal failure (101). Galectin-3 recently failed
to predict functional recovery for new dilated cardiomy-
opathy, whereas LGE data did (109). In addition, ECM
turnover rate and total accumulation can each theoretically
affect biomarker levels.Table 2 Treatments Targeting Myocardial Fibrosis in Development
Category Name
Target/
Mechanism Class
Growth
factors
Pirfenidone TGF-b activity,
inﬂammation
Small molecule
ECM BAY 94-8862 Nonsteroidal
mineralocorticoid
receptor antagonist
Small molecule
ECM GS-6624 Lysyl oxidase–like 2 Monoclonal
antibody, small
molecule
ECM Relaxin/
serelaxin
Fibroblast, myoﬁbroblast,
collagen, MMP-9, MMP-2
Hormone
Adapted from Wynn and Ramalingam (44).
ECM ¼ extracellular matrix; EU ¼ European Union; HHF ¼ hospitalization for heart failure; IPF ¼ idiCollagen biomarker panels (i.e., procollagen type III amino
terminal peptides) appear to predict events (102,110,111)
and are more widely available than ECV. Yet, consensus
has not yet emerged about which biomarkers are the most
robust diagnostically and prognostically (112). ECV has the
advantage of being speciﬁc to the myocardium. Compared
with histological measures of the myocardium, ECV (75,76)
provides higher correlation values than collagen biomarkers
(113). The association with outcomes may be stronger for
ECV. If conﬁrmed, the use of ECV to quantify myocardial
ﬁbrosis would require fewer study participants to identify
associations in future studies (67,83). A limitation of ECV
measures is that they cannot assess the precise composition
and structural modiﬁcations of the ECM, such as extent of
cross-linking, and the accumulation of advanced glycation
end products.Future Directions
Novel therapeutics. Because apparent amelioration of
ECM expansion culminates in improved outcomes, the
myocardial interstitium is an attractive target for drug
development. Newer agents (Table 2) such as potent and
selective nonsteroidal mineralocorticoid antagonists (114),
serelaxin (32,115), and microribonucleic acids (miRs)
(48,116) offer novel ways to treat ECM expansion caused by
myocardial ﬁbrosis. Some medications with demonstrable
efﬁcacy in trials have not extended to the community and
have not shown similar effectiveness in routine practice
(117). Newer and more potent agents to treat ECM
expansion present new opportunities to bridge this gap and
potentially improve outcomes in HF.
Still, some agents intended to speciﬁcally target ﬁbrosis in
HF and other disease states have failed. Previous therapeutic
agents potentially targeting the interstitium and other de-
rangements (e.g., omapatrilat [118], nesiritide [5]) have not
always been successful compared with standards of care,
which illustrates the challenge of developing efﬁcaciousTarget Disease Manufacturer Phase
IPF, hepatic and renal ﬁbroses,
hypertrophic cardiomyopathy
InterMune,
Brisbane,
California
Clinic (approved for
IPF in EU and Japan)
HHF/cardiac ﬁbrosis Bayer
HealthCare,
Berlin, Germany
1/2
Cardiac ﬁbrosis, IPF Gilead Sciences,
Foster City,
California
1/2
HHF, hypertensive heart
disease, vasodilation
Novartis/
Corthera, Basel,
Switzerland
1/2/3
opathic pulmonary ﬁbrosis; MMP ¼ matrix metalloproteinase; TGF ¼ transforming growth factor.
Figure 3 ECV Maps Display Severe Diffuse ECM Expansion Not Detectable With Conventional LGE Imaging
(A) ECV maps for an older patient with heart failure with corresponding T1 maps (T1 data are used to create ECV maps). The ECV maps reveal severe diffuse ECM expansion,
readily apparent in 2 ECV display settings (black arrows); the midmyocardial ECV is 37% in this patient, which is >95th percentile in the Pittsburgh cohort. In contrast, LGE
images show only a small focal abnormality in the inferior right ventricular insertion point (red arrow). (B) Semiautomated quantitative LGE thresholding techniques using
2 common methods fail to identify the severe diffuse ECM expansion present in nulled myocardium. The bright pixels highlighted in pink (red arrows) are minimal. (C) For
comparison, ECV maps from a younger patient without evident cardiomyopathy and a midmyocardial ECV of 25% (which is within the normal ECV range) are shown. Mid-
myocardial ECV is measured to avoid contamination from partial volume effects from limited spatial resolution and/or misregistration errors depicted by the green pixels along
the blood pool and myocardium interface. Note that in A and C, the ECV map window and level settings for the 2 individuals are identical. ECM ¼ extracellular matrix; ECV ¼
extracellular volume fraction; LGE ¼ late gadolinium enhancement.
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lieved to prevent TNF-mediated cardiac ﬁbrosis, was para-
doxically linked to increased TNF bioavailability and
augmentation of TNF cytotoxicity (119,120).
Determinants of ECM expansion. The factors leading to
ECM expansion and especially the identiﬁcation of modi-
ﬁable and nonmodiﬁable risk factors for myocardial ﬁbrosis
remain incompletely understood. At the molecular level,angiogenic factors, various growth factors, proteolytic en-
zymes, and ﬁbrogenic cytokines are among the elements
involved in ﬁbroblast regulation that lead to ECM
expansion (121,122). Transforming growth factor beta,
endothelin-1, angiotensin II, platelet-derived growth factor,
and connective tissue growth factor appear to be some of the
key proteins governing ﬁbroblast activation/differentiation
into alpha-smooth muscle actin–expressing myoﬁbroblasts
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2195that can persist in an activated state (123). These molecules
represent potential therapeutic targets. Connective tissue
growth factor in turn is regulated by miR-30 and -133 (124);
miR-21 is also a key mediator of ﬁbroblast activation (121).
miR therapies targeting the ﬁbroblast and ECM are under
active development (116).
In the setting of coronary artery disease, the mechanisms
of ﬁbrosis in noninfarcted myocardium are unclear (e.g.,
repetitive stunning, increased wall stress, and neurohor-
monal activation) as are the optimal prevention and treat-
ment strategies. The degree to which identiﬁable clinical or
genetic conditions explain myocardial ﬁbrosis (accounting
for measurement error) is unknown. The natural history of
myocardial ﬁbrosis once it is present and whether it is
progressive and inexorable (i.e., whether “ﬁbrosis begets
ﬁbrosis”) also remain poorly deﬁned. The comparative efﬁ-
cacy of drug treatment and timing of any response has not
been adequately investigated. The time and degree to which
exercise can modulate myocardial ﬁbrosis is also unknown.Conclusions
There is an urgent need to improve outcomes in the large
and vulnerable population of patients with HF, particularly
those with HHF. New therapies are needed that focus on
critical disease-modifying pathways intrinsic to the ventricle
without adversely disrupting collagen metabolism in other
organs. Myocardial ECM expansion is an important path-
ophysiological abnormality, likely a major driver of disease
progression in many cases leading to HF and HHF, and it
remains an important therapeutic target. The terms inter-
stitial heart disease (17) and vulnerable myocardial inter-
stitium (38) have been coined to highlight the deleterious
effects of ECM expansion. ECM expansion due to myo-
cardial ﬁbrosis in the ventricle is associated with mechanical,
electrical, and vasomotor dysfunction, with an adverse
prognosis, but it is treatable. Until recently, ECM expansion
has been difﬁcult to image and quantify. Using CMR to
quantify ECM expansion, myocardial ﬁbrosis, and other
cardiac derangements in cardiovascular structure may foster
drug development and provide a mechanistic foundation to
improve care through targeted treatment of speciﬁc disease-
modifying pathways intrinsic to the ventricle. More data are
needed to explore these hypotheses, which merit further
investigation.
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